Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zymeworks Inc. - Common Stock (NY:ZYME)

N/A UNCHANGED
Last Price Updated: 7:00 PM EST, Dec 15, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Zymeworks Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks to Host Third Quarter Results Conference Call
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Completes Plan to Become Delaware Corporation
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Announces Results of Special Meeting
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Reminds Shareholders to Vote FOR its Redomicile
From Zymeworks
Via Business Wire
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research & Development Day
From Zymeworks Inc.
Via Business Wire
News headline image
Independent Proxy Advisory Firm ISS Recommends a Vote FOR the Zymeworks Redomicile
From Zymeworks Inc.
Via Business Wire
News headline image
Independent Proxy Advisory Firm Glass Lewis Recommends Zymeworks Shareholders Vote FOR Redomicile
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at European Society for Medical Oncology Annual Congress
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve Redomicile to Delaware
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial Results
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in Paris
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Reports Inducement Grant to New Chief Scientific Officer
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks to Host Second Quarter Results Conference Call
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Announces Plan to Become a Delaware Corporation
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Announces Participation in Upcoming Investor Conference
From Zymeworks Inc.
Via Business Wire
News headline image
Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Confirms Receipt of Unsolicited, Non-Binding Proposal from All Blue Falcons
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Announces Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks to Host First Quarter 2022 Results Conference Call
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results
From Zymeworks Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.